Information on Echinacea Herb


Echinacea Picture

Echinacea is a "preventative" herb. Not used in any modern commercial drugs today but Echinacea is heralded by many herbalists as one of the very best blood purifiers and an effective antibiotic. Its contains a natural antibiotic that makes it an effective, broad-based infection fighter. It is considered an immune system stimulant which increases production of infection fighting T cells. It is believed to strengthen the body's tissues and protect from attacks of invasive germs.

There are nine species, but only three of them (E. angustifolia, E. pallida, E. purpurea) are used as botanical medicines. Gardeners may recognize echinacea as the purple coneflower. The three species are not interchangeable, although they may sometimes be confused with one another. Each may have a different balance of active compounds. Of course, the roots also differ from the aboveground parts of the plant, though both are utilized medicinally. The chemistry of echinacea is complex, and no single ingredient has been identified as primarily responsible for the therapeutic activity.

One thing to remember is echinacea should be taken on an as-needed basis or at the change of a season. Not continually. Echinacea boosts the immune system but continual use may actually lessen the effectiveness of your own immune system. Maximum time to take the herb has been suggested at six to eight weeks. Echinacea is generally a very safe herb with side effects being very rare even when taken in large doses. One of the problems with echinacea is that the different species may be confused by people gathering the herb from the wild.

Leave your comments

Health News

Surgeon Removes Eight Pound Liver Tumor

The cancerous tumor in Marcus Muhich's liver weighed 8 pounds and was nearly a foot across. Doctors at three major academic medical centers in the Midwest told Muhich his high-grade tumor was inoperable. Then he was referred to Dr... [ read article ]

NIPPV Linked To Increased Hospital Mortality Rates In Small Group Of Patients

Although increased use of noninvasive positive-pressure ventilation (NIPPV) nationwide has helped decrease mortality rates among patients hospitalized with chronic obstructive pulmonary disease (COPD), a small group of... [ read article ]

FDA Approves Label Update For PREZISTA® To Include 192-Week Data In HIV-1-Infected Adult Patients

Starting Treatment Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA® (darunavir) tablets to include 192-week data from the ARTEMIS study... [ read article ]

Recommended Stuff

Our Latest Blog Entries...